UNSPSC 51372204: Phenadoxone

This classification denotes an opioid receptor agonist and opioid with the molecular formula C23H29NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 375W3TA42N, chemically known as 4,4-diphenyl-6-morpholino-3-heptanone but generally known as phenadoxone, which bears US NIH Compound Identifier 10089. European Medicines Agency schedules Phenadoxone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09747MIG. The term PHENADOXONE is an International Non-Proprietary Name.

UNSPSC 51372204 Phenadoxone is a Commodity code that in practice encompasses pharmaceutical procurement across a broader range of medications and therapeutic products than the code name alone suggests. State and local governments soliciting under this code are buying generic multi-source pharmaceuticals, over-the-counter products, naloxone, and supporting health and safety systems through both direct procurements and cooperative purchasing agreements. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The scope of work spans supply agreements with fixed or net-price structures, compliance with cGMP and Drug Supply Chain Security Act requirements, NDC-level product specification, authorized wholesaler relationships, and quarterly or ongoing delivery schedules to health facilities and community health buildings.

Recent activity shows Seminole County, Florida posting IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline; the Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to explore vendor capabilities for a direct-to-manufacturer pharmacy program; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline and July 1, 2026 contract start date. Geographic activity spans Florida, Texas, Minnesota, and participating MMCAP member jurisdictions including Oregon. Vendors must typically maintain authorized wholesaler relationships, carry professional liability and workers' compensation insurance, certify FDA compliance and cGMP adherence, and accept administrative fees of up to 3 percent on purchases.